S1b3inL1 is a macrocyclic peptide that potently inhibits SARS-CoV-2 infection by binding a conserved spike protein site. It demonstrates broad antiviral activity against multiple variants in vitro, making it a valuable research tool for studying viral entry mechanisms and developing therapeutic strategies.